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Background: IL-17 expression was found to be associated with many inflammatory diseases in
humans, such as rheumatoid arthritis, asthma, systemic lupus erythematosus and allograft
rejection and many in vitro studies have indicated a proinflammatory function for IL-17.
Objective: Prognostic value of increased serum IL-17 in asthma patients.
Methods: Serum IL-17 (ELISA) was measured in 85 asthma patients (pts), mean age
46.99  14.1 years, 61% females, 23 mild persistent, 26 moderate persistent and 36 severe
persistent asthma. Using multiple regression analysis (STATISTICA 7), increased serum IL-17
(>20 pg/ml) was tested as risk factor for severe asthma in comparison with ‘‘traditional’’ risk
factors: smoke, NSAID intolerance, obesity, chronic rhinosinusitis, blood eosinophilia, FEV1 at
baseline < 50% predicted (low FEV1).
Results: Medium serum IL-17 values were 14.21 pg/ml in mild asthma, 12.22 pg/ml in
moderate asthma and 24.72 pg/ml in severe asthma. IL-17 values > 20 pg/ml were encoun-
tered in 3(13%) mild asthma pts (p < 0.001 vs. severe asthma), 2(8%) moderate asthma pts.
(p < 0.001 vs. severe asthma), and in 11(31%) severe asthma pts. For severe asthma multiple
regression analysis revealed as independent risk factors IL-17 (p Z 0.000290), NSAID intoler-
ance (p Z 0.000585) and low FEV1 (p Z 0.000059).
Conclusions: IL-17 is increased in severe asthma compared to mild/moderate forms of the
disease and values above 20 pg/ml are an independent risk factor for severe asthma.
ª 2010 Elsevier Ltd. All rights reserved.a Arbore 16, Brasov 500112, Romania. Tel.: þ40 727 849321; fax: þ40 268 471814.
o (I. Agache).
0 Elsevier Ltd. All rights reserved.
1132 I. Agache et al.Introduction
IL-17A is a newly described proinflammatory cytokine
secreted by a subtype of T helper lymphocytes, Th17.1
Increased IL-17A expression was found to be associated
with many chronic inflammatory diseases in humans, such
as rheumatoid arthritis, asthma, systemic lupus eryth-
ematosus and allograft rejection.2
The role of IL-17/Th17 cells in asthma is yet unclear. In
a murine model of asthma IL-23 and Th17 cells not only
induce Th17-cell-mediated neutrophilic airway inflamma-
tion, but also up-regulate Th2-cell-mediated eosinophilic
airway inflammation.3
In the sputum of asthma patients, including moderate/
severe asthma under inhaled steroid treatment, the IL-17
mRNA was increased and correlated with increased IL-8
mRNA and with sputum neutrophilia. IL-17 mRNA was also
correlated with mRNA for the CD3 gamma chain, thus sug-
gesting the lymphocytic origin (Th17) of the cytokine.4 IL-17A
and IL-17F were suggested to promote neutrophilic inflam-
mation of the airways through increased release of CXCL1 and
CXCL8 (IL-8) from bronchial epithelium.5 Tissue IL-17
expression is increased in bronchial biopsies from patients
with asthma and stimulates bronchial fibroblasts to secrete
cytokines.6 In another study increased sputum IL-17 was
correlated with methacholine bronchial hyperreactivity.7
However, in an attempt to identify the specific sputum
biomarkers that distinguish different subtypes of severe
asthma, neither IL-17 or other cytokine measured in induced
sputum correlated with persistent airway obstruction.8
Systemic inflammation associated with asthma and it’s
relation to asthma severity is well demonstrated and rec-
ognized.9e11 There are few data on serum IL-17A levels in
asthma patients. In one study allergic asthma patients had
higher plasma IL-17 and IL-6 concentrations than normal
controls, although the differences were not statistically
significant, while IL-18, IL-12, IL-10, IL-13 were significantly
higher compared to controls.12
The current study was undertaken to determine whether
increased serum IL-17A has a prognostic value for adult
asthma patients.
Methods
Study design and subjects
The study protocol was approved by the local Ethics
Committee (IRB). The study has a cross-sectional design and
is based both in a private setting and in a community
hospital. Adults/adolescents patients with doctor diag-
nosed persistent asthma were selected both from the
private practice and the hospital database. 233 subjects
were contacted by phone, 180 attended the clinic and
received both written and oral information, 127 subjects
gave their oral consent to participate in the study.
Asthma was diagnosed both by history and clinical
examination and by the presence at inclusion of reversible
airway obstruction, defined as an increase of FEV1 by  12%
15 min after inhalation of salbutamol 400 mg per spacer.
Patients were divided into 3 subgroups: mild, moderate and
persistent asthma (GINA 2005).We excluded patients with doctor diagnosed acute or
chronic inflammatory diseases or with autoimmune diseases
and also patients with increased serum C reactive protein,
with increased fractions of a2, b or g globulins at protein
electrophoresis, with cryoglobulins or with positive auto-
immunity screen panel testing. ChurgeStrauss syndrome
was excluded if the all following were present: normal
chest radiograph, absence of ANCA antibodies and no signs
of systemic involvement (mono- or polyneuropathy, skin
lesions, muscular or joint symptoms, fever).
Asthma patients included were evaluated at baseline for:
 Demographic features (age, sex)
 Smoking status (history)
 General and pulmonary clinical examination, including
height, weight and body mass index
 Atopic status (at least one skin-prick test positive from
the common aeroallergens tested: house dust mites,
cat, dog, molds, cockroaches, grass pollen, trees
pollen, weeds pollen; positive skin-prick test if wheal
diameter of allergen/wheal diameter of histamine > 1
and a mean wheal size  3 mm)
 Asthma duration, treatment and severity (GINA 2005
criteria for mild/moderate/severe persistent asthma)
 Lung function (ERS/ATS guidelines): FEV1 with revers-
ibility testing 15 min after a bronchodilator; FEF 25e75
and MEF50 as indicators of small airway obstruction
 Presence of co-morbidities: non-steroidal anti-
inflammatory drugs intolerance (history), moderate/
severe persistent rhinitis (as defined by the ARIA
document) or chronic rhinosinusitis (confirmed by an
ENT specialist), obesity (body mass index >25)
 Blood eosinophils and neutrophils; eosinophilia defined
as > 4% eosinophils at the differential cell count
 Serum IL-17A and TNF-a: IL-17A was measured using
a third generation ELISA (reagent provided by DRG
Diagnostics). The cut-off value was set at 20 pg/ml,
close to median values for serum IL-17A identified in
a previous study in allergic asthma.12 TNF-a was
measured using a chemiluminescent technique (reagent
provided by Immulite). The cut-off value was set at
8.2 pg/ml, as recommended by the manufacturer. We
measured both IL-17A and TNF-a since they both
promote systemic inflammation and could be corre-
lated or act independently
At least 4 weeks separated the end of an asthma exac-
erbation and patient baseline evaluation. No systemic anti-
inflammatory treatment was allowed for at least 4 least
weeks before baseline evaluation.
A control group of 11 atopics non-asthmatics, mean age
33.73  13.18years old, 27.3% females, was used to
compare the IL-17A serum levels with the values measured
in asthmatic subjects.Main outcomes
Serum IL-17A and TNF-a in relation with asthma severity
Serum IL-17 and TNF-a were measured at inclusion and
compared between mild, moderate and persistent asthma
patients.
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The following risk factors for severe asthma were consid-
ered in the multiple regression analysis: moderate/severe
persistent rhinitis/chronic rhinosinusitis, smoker, obesity,
non-steroidal anti-inflammatory drugs intolerance, blood
eosinophilia, FEV1 at baseline < 50% predicted (low FEV1),
atopic status, and serum IL-17A > 20 pg/ml.
Asthmatic phenotypes in relation with increased serum
IL-17
We tested if increased serum IL-17A (>20 pg/ml) is corre-
lated with other phenotypic features of asthma such as
associated atopy, non-steroidal anti-inflammatory drugs
intolerance, moderate/severe persistent rhinitis/chronic
rhinosinusitis, smoker, obesity, FEV1 at baseline < 50%
predicted, small airways obstruction, blood eosinophilia
and neutrophilia, increased serum TNF-a.
Analysis of the subgroup of severe asthma patients
For the subgroup of severe asthma we compared patients
with increased serum values of IL-17A with patients with
normal serum IL-17A for: demographic characteristics, lung
function, mean asthma duration, asthma regular treatment
and for risk factors for severe asthma mentioned above.
Data analysis
Data are presented as median (range) values unless
otherwise stated. All data were analyzed with STATISTICA
7. The differences between mild, moderate and severe
persistent asthma group (Table 1) were tested using the T-
test for independent samples. The analysis of the differ-
ences in medium IL-17A serum concentration betweenTable 1 Characteristics of persistent asthma patients at inclus
Mi
23
Age (years) mean 41
range 17
Sex ratio (% females) 73
Asthma duration (years) mean 9.2
range 0.5
FEV1% predicted mean 93
range 79
Number of eosinophils
(cells/mm3)
mean 28
range 30
Eosinophils (%) mean 3.9
range 0.1
Asthma treatment ICS 6(2
ICS þ LABA 3(1
ICS þ LTRA 0
ICS þ LABA þ LTRA 0
LTRA 14
ICS > 1500 mg/day alone
or in combination
with LABA/LTRA
0
No treatment 0
*p < 0.05 severe vs. mild asthma; **p < 0.05 severe vs. mild and
ICS Z Inhaled steroids; LABA Z long acting beta 2 agonists; LTRA Zpatients with mild, moderate or severe asthma and for the
number of patients with IL-17A > 20 pg/ml in each asthma
severity group used the T-test for independent samples.
Risk factors for severe asthma evolution were tested in the
multiple linear regression. Correlations between
increased serum IL-17A and other phenotypic features of
asthma were evaluated using the Pearson correlation test.
For the analysis of the subgroup of severe asthma patients
features we used both T-test and Chi-test. To avoid falsely
positive conclusions, the significance level at each test
was set to 0.05.
Results
From the initial 127 asthma patients consenting to partici-
pate into the study, 85 subjects were selected, after
excluding patients with concomitant acute or chronic
inflammatory diseases or with autoimmune diseases.
Subject characterisation
Mean age of asthma patients was 46.99  14.1 years (limits
15e73 years old) and 52 (61.18%) were females. All subjects
were Caucasians, with no ethnic differences. Mean asthma
duration was 12.64  1.19 years (limits 0.58e50 years).
According to GINA criteria 23 (27.06%) patients had mild
persistent asthma, 26 (30.59%) moderate persistent asthma
and 36 (42.35%) severe persistent asthma.
Patients with severe persistent asthma were significantly
(p Z 0.005329) older (mean age 50.83  2.08 years)
compared to mild asthma patients (mean age
41.39  2.44years) and asthma duration was significantlyion.
ld asthma
patients
Moderate
asthma 26 patients
Severe asthma
36 patients
.39  2.44 46.62  3.27 50.83  2.08*
e63 15e69 24e73
.91% 53.85% 58.33%
6  1.90 9.30  1.59 17.19  2.08**
8e34 1e38 2.5e50
.74  1.87 80.42  2.38*** 61.06  2.68**
e110 59e100 26e107
1.35  36.72 399.19  57.12 396.17  49.52
e648 70e1228 100e1280
2  0.50 5.31  0.77 4.96  0.65
5e8.50 0.20e16.60 0.10e16.20
6.09%) 5(19.23%) 4(11.11%)
3.04%) 12(46.15%) 23(63.89%)
6(23.08%) 1(2.78%)
8(22.22%)
(60.87%) 3(11.53%) 0
0 25(69.44%)
0 0
vs. moderate asthma; ***p < 0.05 mild vs. moderate asthma;
leucotriene receptors antagonists.
Figure 1 Mean serum IL-17 levels in study groups.
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asthma patients (17.19  2.08 years) compared to
moderate (9.304  8.12 years) and milder forms of the
disease (9.26  1.9 years). Sex ratio was not significantly
different between severity groups. FEV1 was significantly in
severe asthma patients compared to the mild
(p Z 4.56  1012) and moderate asthma (p Z 0.000003)
patients groups, and significantly lower in the moderate
asthma patients compared to mild asthma group
(p Z 0.000091) (Table 1). Asthma treatment at inclusion is
also described in Table 1.
Serum IL-17 and TNF-a values
In the control group of atopic non-asthmatics mean serum
IL-17A was 8.748  11.657 pg/ml, highest value was
33.483 pg/ml. Serum IL-17A was below the detection
threshold in 2 cases.
In the asthma patients group highest serum IL-17A value
was 109.469 pg/ml, lowest value 4.921 pg/ml. IL-17A
values > 20 pg/ml were encountered in 16 patients:Table 2 Incidence of risk factors for severe asthma in study su
Risk factor Incidence in the mild
asthma group (23 subjects)
Smoke 9(20.7%)
NSAID intolerance 4(17.39%)
Atopy 14(60.87%)
Obesity 12(52.17%)
Moderate/severe persistent
rhinitis/chronic rhinosinusitis
21(91.3%)
Blood eosinophilia 10(43.48%)
FEV1 < 50% predicted 0
Age>50 years old 7(30.43%)
Asthma duration > 5 years 22(95.65%)
IL-17 > 20 pg/ml 3(13.04%)
NSAID Z non-steroidal anti-inflammatory drugs.3(13.04%) mild asthma patients (p < 0.001 vs. severe
asthma), 2(7.69%) moderate asthma patients (p < 0.001 vs.
severe asthma), and in 11(30.56%) severe asthma patients.
IL-17 A values > 100 pg/ml were encountered in 2 patients
with severe persistent asthma. Mean serum IL-17 values
were 14.21  3.62 pg/ml in mild asthma, 12.22  3.71 pg/
ml in moderate asthma and 24.72  4.87 pg/ml in severe
asthma (Fig. 1).
Highest serum TNF-a value was 37.7 pg/ml, lowest value
4 pg/ml. TNF-a values > 8.2 pg/ml were encountered in 55
patients: 13(56.52%) mild asthma patients, 18(69.23%)
moderate asthma patients and in 24(66.67%) severe asthma
patients. Mean serum TNF-a values were 8.88  0.6 pg/ml
in mild asthma, 11.31  1.5 pg/ml in moderate asthma and
12.02  1.17 pg/ml in severe asthma.
Risk factors for severe asthma
Increased serum IL-17 (>20 pg/ml) was tested in the
multiple regression analysis model as risk factor for severe
asthma in comparison with ‘‘traditional’’ risk factors:
smoker, non-steroidal anti-inflammatory drugs intolerance,
obesity, moderate/severe persistent rhinitis or chronic
rhinosinusitis, blood eosinophilia, FEV1 at baseline < 50%
predicted (low FEV1). The incidence of analyzed risk factors
is displayed in Table 2.
For severe asthma multiple regression analysis revealed
as independent risk factors IL-17 > 20 pg/ml,
(p Z 0.000257), non-steroidal anti-inflammatory drugs
intolerance (p Z 0.000649) and low FEV1 (p Z 0.000043)
(Table 3).
Correlations between increased serum IL-17 and
other phenotypic features of asthma
Serum IL-17 > 20 pg/ml was negatively correlated with
increased blood neutrophils (r Z  0.3376, p Z 0.047) and
with small airways obstruction (rZ 0.4526, pZ 0.006) and
was not correlated with the presence of atopy, blood eosino-
philia, smoker,obesity,moderate/severepersistent rhinitisor
chronic rhinosinusitis, non-steroidal anti-inflammatory drugs
intolerance, FEV1 < 50% predicted or increased serum
TNF-a (Table 4).bgroups.
Incidence in the moderate
asthma group (26 subjects)
Incidence in the severe
asthma group (36 subjects)
11(42.31%) 13 (36.11%)
9(34.61%) 24(66.67%)
11(42.31%) 13 (36.11%)
14(53.85%) 26(30.59%)
21(80.77%) 32(88.89%)
15(57.69%) 14(38.89%)
0 11 (30.56%)
12(46.15%) 22(61.11%)
25(96.15%) 26(100%)
2(7.69%) 11 (30.56%)
Table 3 Risk factors for severe asthma in the multiple regression analysis model.
Beta Standard Error
of Beta
B Standard Error
of B
t(73) p-level
Smoke 0.010273 0.092371 0.010370 0.093245 0.11121 0.911746
NSAID intolerance 0.346923 0.097467 0.345615 0.097099 3.55940 0.000649
Atopy 0.076304 0.098527 0.075581 0.097593 0.77445 0.441099
Obesity 0.002673 0.104863 0.002714 0.106457 0.02549 0.979728
Moderate/severe persistent
rhinitis/chronic rhinosinusitis
0.028323 0.097938 0.041392 0.143129 0.28919 0.773233
Blood eosinophilia 0.094935 0.093798 0.093847 0.092722 1.01213 0.314731
FEV1 < 50% predicted 0.400498 0.092198 0.609701 0.140359 4.34388 0.000043
IL-17 > 20 pg/ml 0.352762 0.091920 0.442894 0.115406 3.83770 0.000257
NSAID Z non-steroidal anti-inflammatory drugs.
Table 4 Correlation between increased serum IL-17 and
other phenotypic features of asthma.
Parameter Coefficient p value
Atopic status 0.1290 0.453
Moderate/severe persistent
rhinitis or chronic
rhinosinusitis
0.2345 0.169
Smoke 0.1221 0.478
Obesity 0.0075 0.965
NSAID intolerance 0.1706 0.320
FEV1 < 50% predicted 0.3091 0.067
Small airways obstruction 0.4526 0.006
Blood eosinophilia 0.0210 0.247
Blood neutrophilia 0.3376 0.047
TNF-a>8.2 pg/ml 0.0606 0.729
NSAID Z non-steroidal anti-inflammatory drugs.
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asthma
Compared to severe asthma patients with normal values of
IL-17A versus those with severe asthma and IL-17A > 20 pg/
ml there was significantly lower incidence of smokers
(pZ 0.0005), of subjects >50 years old (pZ 0.0002) and of
non-steroidal anti-inflammatory drugs intolerance
(p Z 0.0010) and significantly higher incidence of eosino-
philia (p Z 0.0471), atopy (0.0025) and preserved lung
function (p Z 0.0000) (Table 5).
Discussion
No data exist on serum IL-17 in asthma, most of the studies
concentrated on measuring IL-17 in sputum or bronchial
biopsies. We chose serum IL-17 as an indicator for severe
asthma because it is easily measurable compared to its
determination in induced sputum, broncho-alveolar lavage
or bronchial biopsies. Our study demonstrates that it can be
use to predict asthma severity since it is both increased in
severe asthma compared to mild/moderate forms of the
disease and is an independent predictor of severe asthma.
The results are in concordance with other studies under-
lying the link between systemic inflammation and asthma
severity.9,10 Also, a trend towards increased production of
IL-17 was reported for another phenotype of severe
asthma, ChurgeStrauss syndrome.13
Increased serum IL-17 was more discriminative for
severe asthma compared to serum TNF-a. Also, there was
no correlation between increased serum IL-17 and serum
TNF-a, thus both depicting separate phenotypes of asthma.
Although median values of serum IL-17 were not
discriminative for severe asthma compared to mild/
moderate forms of the disease, there were significantly
more asthma patients with values above 20 pg/ml in the
severe asthma group compared to mild or moderate asthma
patients. Very high values for serum IL-17 (>100 pg/ml)
were encountered only in the severe asthma patient’s
subgroup. The dissociation between mean values and indi-
vidual values underlines the heterogeneity of severe
asthma, with increased serum IL-17 more relevant for
a subphenotype of severe asthma, non-smokers, without
non-steroidal anti-inflammatory drugs intolerance, with
preserved lung function and with normal serum TNF-a.The cross-sectional nature of the study may dampen the
resulting prognostic value of increased serum IL-17 for
severe asthma. None-the-less, many validated parameters
that we actually use for predicting asthma severity came
first from cross-sectional studies, using the same method-
ology that we used.14,15 Validation of serum IL-17 in
a prospective cohort of severe asthma patients is however
warranted.
Patients with severe persistent asthma were significantly
older compared to mild asthma patients and there are
relevant differences between study groups in term of
treatment. Also, the control group of atopics non-
asthmatics were younger and had less females compared
to the study groups. These demographic differences should
be taken into account when interpreting the main
outcomes of the study.
The inverse correlation with blood neutrophils is
surprising, since most of the studies associate IL-17 with
neutrophilic inflammation.1,4 The association in this case
may be true for lung inflammation and the decreased blood
neutrophils may reflect their recruitment into the lungs.
The relation between increased serum IL-17 and lung
function is interesting. There was an inverse correlation
with small airways obstruction (as evaluated by FEF 25e75
and MEF50) and there is also a tendency towards inverse
relation, although not statistically significant, with low lung
Table 5 Characterisation of severe asthma patients with high levels of serum IL-17 (>20 pg/ml).
Serum IL-17 > 20 pg/ml
(11 subjects)
Serum IL-17 < 20 pg/ml
(25 subjects)
Age (years) mean 47.64  4.04 52.24  2.42
range 24e63 26e73
Sex ratio (% females) 72.73% 52%
Asthma duration (years) mean 14.29  3.58 18.47  2.55
range 3e40 2.5e50
Asthma treatment ICS 3 (27.3%) 1(4%)
ICS þ LABA 5(45.5%) 18(72%)
ICS þ LTRA 1(9.1%) 0
ICS þ LABA þ LTRA 2(18.2%) 6(24%)
ICS > 1500 mg/day alone
or in combination
with LABA/LTRA
6(54.5%) 19(76%)
FEV1 % predicted mean 72.73  4.60* 55.92  13.79
range 48e107 26e78
Number of eosinophils
(cells/mm3)
mean 551.82  102.36* 324.83  244.69
range 200e1280 100e1000
Eosinophils (%) mean 7.26  1.40* 3.90  2.95
range 2e16.20 0.10e11.80
Smoke 3(27.3%)** 10(40%)
NSAID intolerance 6(54.5%)** 18(72%)
Atopy 5(45.5%)** 8(32%)
Obesity 9(81.8%) 17(68%)
Moderate/severe persistent
rhinitis/chronic rhinosinusitis
11(100%) 21(84%)
Blood eosinophilia 6(54.5%)** 8(32%)
FEV1 < 50% predicted 1(9.1%)** 10(40%)
Age>50 years old 5(45.5%)** 17(68%)
Asthma duration > 5 years 8(72.7%) 18(72%)
T-test: *p < 0.05; Chi-test: **p < 0.05.
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In the analysis of severe asthma patients subgroup FEV1 %
predicted was significantly higher and the number of
subjects with FEV1 <50% significantly lower in association
with increased serum levels of IL-17A. It seems that IL-17 is
increased in subgroup of severe asthma patients with more
preserved lung function. In another study sputum IL-17 was
associated with increased bronchial hyperreactivity to
methacholine.7 Increased IL-17 may thus characterise
a peculiar lung remodeling with increased bronchial smooth
muscle and less fibrosis.
There is also a tendency for an inverse relationship
between smoking and increased serum IL-17 and the inci-
dence of smokers is significantly lower in severe asthma
patients with increased serum IL-17 compared to severe
asthmatics with normal values of IL-17A. It may seem that
increased serum IL-17 is more powerful as a risk factor in
non-smoking asthma patients. The same pattern (tendency
towards an inverse relationship and decreased incidence in
severe asthmatics with high serum IL-17) can be observed
for increased serum IL-17 and non-steroidal anti-inflam-
matory drugs intolerance. It may also be true that
increased serum IL-17 may be more valuable in severe
asthma patients without non-steroidal anti-inflammatory
drugs intolerance.Inhaled steroids, even at high concentrations (>1500 mg/
day) did not influence serum values of IL-17. The effect of
systemic steroids is unknown since per protocol the evalu-
ation was done at least 4 weeks after an asthma exacer-
bation resolution.
There are no data correlating sputum/bronchial biopsies
IL-17 with serum IL-17. Since both were demonstrated to be
increased in severe asthma, a study evaluating the link
between local (pulmonary) and systemic (serum) IL-17 is
more than appropriate and desired.
In conclusion serum IL-17 is increased in a subgroup of
patients with severe asthma compared to mild/moderate
forms of the disease and values above 20 pg/ml are an
independent risk factor for severe asthma. Also, increased
serum IL-17 did not correlate with other phenotypic
features of asthma (atopy, blood eosinophilia, smoker,
obesity, non-steroidal anti-inflammatory drugs intolerance,
moderate/severe persistent rhinitis or chronic rhinosinusi-
tis, FEV1 < 50% predicted, increased serum TNF-a) and thus
could depict a special subphenotype of severe asthma.Conflict of interest
None.
Serum IL-17 in severe asthma 1137References
1. Tato CM, O’Shea J. What does it mean to be just 17? Nature
2006;441:166e8.
2. Pe`ne J, Chevalier S, Preisser L, et al. Chronically inflamed
human tissues are infiltrated by highly differentiated Th17
lymphocytes. J Immunol 2008;180(11):7423e30.
3. Wakashin H, Hirose K, Maezawa Y, et al. IL-23 and Th17 cells
enhance Th2-cell-mediated eosinophilic airway inflammation
in mice. Am J Respir Crit Care Med 2008;178(10):1023e32.
4. Bullens DM, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of
asthmatic patients: linking T cell driven inflammation and
granulocytic influx? Respir. Res. 2006;7:135.
5. Laan M, Lotvall J, Chung KF, Linden A. IL-17F induced cytokine
release in human bronchial epithelial cells in vitro: role of
mitogen-activated protein (MAP) kinases. Br J Pharmacol 2001;
133(1):200e6.
6. Molet S, Hamid Q, Davoine F, Nutku E, et al. IL-17 is increased in
asthmatic airways and induces human bronchial fibroblasts to
produce cytokines. J Allergy Clin Immunol 2001;108(3):430e8.
7. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum
correlates with airway hyperresponsiveness to methacholine.
Respir Med 2003;97(6):726e33.
8. KaminskaM,FoleyS,MaghniK,etal.Airway remodeling insubjects
with severe asthma with or without chronic persistent airflow
obstruction. J Allergy Clin Immunol 2009;124(1):45e51. e1-4.9. Kasayama S, Tanemura M, Koga M, Fujita K, Yamamoto H,
MiyatakeA. Asthma is an independent risk for elevation of plasma
C-reactive protein levels. Clin Chim Acta 2009;399(1e2):79e82.
10. Qian FH, Zhang Q, Zhou LF, et al. High-sensitivity C-reactive
protein: a predicative marker in severe asthma. Respirology
2008;13(5):664e9.
11. Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Mroczko B,
Szmitkowski M, Bodzenta-Lukaszyk A. High-sensitivity
C-reactive protein in the exhaled breath condensate and
serum in stable and unstable asthma. Respir Med 2009;
103(3):379e85.
12. Wong CK, Ho CY, Ko FW, et al. Proinflammatory cytokines (IL-
17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4,
IL-10 and IL-13) in patients with allergic asthma. Clin Exp
Immunol 2001;125(2):177e83.
13. Saito H, Tsurikisawa N, Tsuburai T, Oshikata C, Akiyama K.
Cytokine production profile of CD4þ T cells from patients with
active ChurgeStrauss syndrome tends toward Th17. Int Arch
Allergy Immunol 2009;149(Suppl. 1):61e5.
14. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH.
Factors associated with persistent airflow limitation in severe
asthma. Am J Respir Crit Care Med 2001;164(5):744e8.
15. Lee JH, Haselkorn T, Borish L, et al. Risk factors associated
with persistent airflow limitation in severe or difficult-to-treat
asthma: insights from the TENOR study. Chest 2007;132(6):
1882e9.
